Evidence map›Paper›PMID 26984249›Full record

ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2016

Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols.

Judith A E M Zecha, Judith E Raber-Durlacher, Raj G Nair, Joel B Epstein, Sharon Elad, Michael R Hamblin, Andrei Barasch, Cesar A Migliorati, Dan M J Milstein, Marie-Thérèse Genot and 10 more

3 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 108 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 5 pooled it
19.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04082793 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Comparison of Photobiomodulation Therapy and Sonophoresis in Improving Tempomandibular Joint Mobility and Quality of Life Among Head and Neck Cancer Survivors (PBMT-S Trial): A Triple-Blind, Randomized Controlled Trial.

TypeinterventionalSponsorAsir John SamuelRan2020 to 2021Enrolled48ConditionsHead and Neck Cancer, TrismusArmsPhotobiomodulation therapy with mandibular exercises, Sonophoresis with mandibular exercises
NCT05663723 nacompletednot on this mapstarted 2023, after this paper: background citation

Photobiomodulation for Prevention of Chemotherapy-induced Peripheral Neuropathy in Women With Breast Cancer

TypeinterventionalSponsorErica Alves Nogueira FabroRan2023 to 2024Enrolled186ConditionsPeripheral Nervous System Diseases AND Breast NeoplasmsArmsIntervention group with the IV and V LED board, Intervention group with the IV, V and Violet LED board, Control group with LED board without emitting light
NCT05757024 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Effect Of High Power Laser Therapy On Radiotherapy Induced Trismus In Head And Neck Cancer Patients

TypeinterventionalSponsorCairo UniversityRan2022 to 2023Enrolled44ConditionsTrismusArmshigh power laser therapy
3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 5 syntheses or guidelines pooled it, 236 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Photobiomodulation for Preventive Therapy of Recurrent Herpes Labialis: A 2-YearPhotobiomodulation, photomedicine, and laser surgery · 2022
    Trial
  11. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Trial
  12. Trial
  13. Intraoral versus extraoral photobiomodulation therapy in the prevention of oral mucositis in HSCT patients: a randomized, single-blind, controlled clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Biophysical skin measurements to evaluate the effectiveness of photobiomodulation therapy in the prevention of acute radiation dermatitis in breast cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Trial
  18. Photobiomodulation to minimize talquetamab-associated dysgeusia and xerostomia in multiple myeloma: a brief report of four cases.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  19. Article
  20. Review

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 6 countries.

Judith A E M ZechaDepartment of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
Judith E Raber-DurlacherDepartment of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
Raj G NairOral Medicine Oral Pathology and Human Diseases, Menzies Health Institute Queensland and Oral Medicine Consultant, Department of Haematology and Oncology/Cancer Services, Gold Coast University Hospital, Queensland Health, Queensland, Australia.
Joel B EpsteinSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
Sharon EladDivision of Oral Medicine, Eastman Institute for Oral Health, and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, 14620, USA.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, 02114, USA.
Andrei BaraschDivision of Oncology, Weill Cornell Medical Center, New York, NY, USA.
Cesar A MiglioratiDepartment of Diagnostic Sciences and Oral Medicine, Director of Oral Medicine, College of Dentistry, University of Tennessee Health Science Center, 875 Union Ave. Suite N231, Memphis, TN, 38163, USA.
Dan M J MilsteinDepartment of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
Marie-Thérèse GenotLaser Therapy Unit, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium.
Liset LansaatAntoni van Leeuwenhoek Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ron van der BrinkDivision of Otolaryngology and Head and Neck Surgery, City of Hope, Duarte, CA, 91010, USA.
Josep Arnabat-DominguezDepartment of Oral Surgery, Faculty of Dentistry, University of Barcelona, Barcelona, Spain.
Lisette van der MolenAntoni van Leeuwenhoek Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Irene JacobiAntoni van Leeuwenhoek Department of Head and Neck Oncology and Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Judi van DiessenAntoni van Leeuwenhoek Department of Radiation Oncology, Amsterdam, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Jan de LangeDepartment of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
Ludi E SmeeleDepartment of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
Mark M SchubertSeattle Cancer Care Alliance (SCCA), Oral Medicine, 825 Eastlake Ave E Ste G6900, Seattle, WA, 98109, USA.
René-Jean BensadounWorld Association for Laser Therapy (WALT) Scientific Secretary, Centre de Haute Energie (CHE), 10 Bd Pasteur, 06000, Nice, France. renejean.bensadoun@che-nice.com.
The Netherlands Cancer Institute · NLAcademic Medical Center · NLCity of Hope · USCentre de Haute Energie · FRCornell University · USInstitut Jules Bordet · BEMassachusetts General Hospital · USQueensland Health · AUSeattle Cancer Care Alliance · USUniversitat de Barcelona · ESUniversity of Amsterdam · NLUniversity of Rochester Medical Center · USUniversity of Tennessee Health Science Center · US

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
NIAID NIH HHS R01 AI050875
6 · The paper itself

Abstract

purposeThere is a large body of evidence supporting the efficacy of low-level laser therapy (LLLT), more recently termed photobiomodulation (PBM) for the management of oral mucositis (OM) in patients undergoing radiotherapy for head and neck cancer (HNC). Recent advances in PBM technology, together with a better understanding of mechanisms involved and dosimetric parameters may lead to the management of a broader range of complications associated with HNC treatment. This could enhance patient adherence to cancer therapy, and improve quality of life and treatment outcomes. The mechanisms of action, dosimetric, and safety considerations for PBM have been reviewed in part 1. Part 2 discusses the head and neck treatment side effects for which PBM may prove to be effective. In addition, PBM parameters for each of these complications are suggested and future research directions are discussed.

methodsNarrative review and presentation of PBM parameters are based on current evidence and expert opinion.

resultsPBM may have potential applications in the management of a broad range of side effects of (chemo)radiation therapy (CRT) in patients being treated for HNC. For OM management, optimal PBM parameters identified were as follows: wavelength, typically between 633 and 685 nm or 780-830 nm; energy density, laser or light-emitting diode (LED) output between 10 and 150 mW; dose, 2-3 J (J/cm(2)), and no more than 6 J/cm(2) on the tissue surface treated; treatment schedule, two to three times a week up to daily; emission type, pulsed (<100 Hz); and route of delivery, intraorally and/or transcutaneously. To facilitate further studies, we propose potentially effective PBM parameters for prophylactic and therapeutic use in supportive care for dermatitis, dysphagia, dry mouth, dysgeusia, trismus, necrosis, lymphedema, and voice/speech alterations.

conclusionPBM may have a role in supportive care for a broad range of complications associated with the treatment of HNC with CRT. The suggested PBM irradiation and dosimetric parameters, which are potentially effective for these complications, are intended to provide guidance for well-designed future studies. It is imperative that such studies include elucidating the effects of PBM on oncology treatment outcomes.

Indexed as

Clinical ProtocolsChemoradiotherapyDrug-Related Side Effects and Adverse ReactionsHead and Neck NeoplasmsHumansLow-Level Light TherapyChemotherapyHead and neck cancerLLLTLow-level laser therapyLow-level light therapyMucositisOrofacial complicationsPBMPhotobiomodulationRadiation therapy

Identifiers

PMID26984249
PMCPMC4846551
OpenAlexW2310338326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.